Centessa Pharmaceuticals' (CNTA) "Buy" Rating Reaffirmed at Guggenheim

Guggenheim reissued their buy rating on shares of Centessa Pharmaceuticals (NASDAQ:CNTA - Free Report) in a report released on Monday morning,Benzinga reports.

Separately, TD Cowen assumed coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $25.83.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA traded down $0.12 during trading hours on Monday, hitting $17.88. 611,092 shares of the company were exchanged, compared to its average volume of 724,151. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. Centessa Pharmaceuticals has a 52-week low of $7.75 and a 52-week high of $19.09. The stock has a market capitalization of $2.36 billion, a price-to-earnings ratio of -11.68 and a beta of 1.53. The company's 50 day moving average price is $16.80 and its 200-day moving average price is $15.56.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.05. As a group, research analysts forecast that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction on Monday, November 25th. The stock was sold at an average price of $17.66, for a total value of $176,600.00. Following the completion of the sale, the insider now directly owns 183,266 shares of the company's stock, valued at approximately $3,236,477.56. The trade was a 5.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.89, for a total value of $928,950.00. Following the transaction, the chief executive officer now directly owns 575,661 shares in the company, valued at approximately $9,722,914.29. The trade was a 8.72 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 452,652 shares of company stock worth $7,800,532. Corporate insiders own 11.59% of the company's stock.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of CNTA. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock valued at $40,000 after purchasing an additional 826 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Centessa Pharmaceuticals by 103.1% in the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company's stock worth $48,000 after acquiring an additional 1,509 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth $187,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Centessa Pharmaceuticals by 99.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company's stock valued at $217,000 after acquiring an additional 6,785 shares in the last quarter. Finally, Harbour Capital Advisors LLC purchased a new position in Centessa Pharmaceuticals in the third quarter valued at $259,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.